Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 25, 2021 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Appoints Head of Research & Clinical Development

NEW YORK and CLEVELAND, May 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Vishwas...
May 18, 2021 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Reports First Quarter Financial Results

Patient enrollment ongoing for EB-101 pivotal Phase 3 VIITAL™ study Positive interim MPS III data presented at 17th Annual WORLDSymposium; additional neurocognitive assessments of patients treated in...
April 20, 2021 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting

NEW YORK and CLEVELAND, April 20, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data from its...
April 19, 2021 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors

NEW YORK and CLEVELAND, April 19, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Dr. Leila...
March 25, 2021 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors

NEW YORK and CLEVELAND, March 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of two new...
March 24, 2021 16:01 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress

Fourth patient treated in pivotal Phase 3 VIITAL™ study of EB-101 in RDEB after successful Type B meeting with FDA Positive new interim data from MPS IIIA and MPS IIIB programs presented at 17th...
March 22, 2021 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer

NEW YORK and CLEVELAND, March 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso,...
February 22, 2021 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

NEW YORK and CLEVELAND, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company will present...
February 12, 2021 11:36 ET | Source: Abeona Therapeutics Inc.

New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy

In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained...
February 02, 2021 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™

NEW YORK and CLEVELAND, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it will host a live...